Gossamer bio announces completion of enrollment in registrational phase 3 prosera study for the treatment of pah

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced enrollment completion for the ongoing, global registrational phase 3 prosera study evaluating seralutinib in functional class ii and iii pah patients. gossamer bio and t.
GOSS Ratings Summary
GOSS Quant Ranking